Search results for "FAST"

showing 10 items of 821 documents

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

2014

Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these clai…

MaleSettore MED/09 - Medicina Internaendocrine system diseasesHSM MEDHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsAnticholesteremic Agents/adverse effectsMedizin1567-5688ComorbidityType 2 diabetesPharmacologyDiabeteHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosageCardiovascularFasting/bloodCohort StudiesRisk FactorsAnticholesteremic Agents/administration & dosageDiabetes Mellitus Type 2/prevention & controlMulticenter Studies as TopicMedicineT2DDiabetisAnticholesteremic AgentsDiabetesHemoglobin A Glycosylated/analysisFastingGeneral MedicineMiddle AgedDiabetogenicityCVDClinical PracticeObservational Studies as TopicCholesterol LDL/bloodCardiovascular DiseasesPractice Guidelines as Topiclipids (amino acids peptides and proteins)Disease SusceptibilityCardiology and Cardiovascular MedicineRisk assessmentCardiovascular Diseases/prevention & controlCohort studyAdultmedicine.medical_specialtyStatinHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic usemedicine.drug_classAnticholesteremic Agents/therapeutic useHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyDiabetes Mellitus Type 2/etiologyRisk AssessmentMulticenter Studies as Topic/statistics & numerical dataPrediabetic StateMeta-Analysis as TopicDiabetes mellitusInternal MedicineHumansIntensive care medicinePrediabetic State/epidemiologyGlycated HemoglobinStatins; Diabetes; Diabetogenicity; T2D; Cardiovascular; CVDbusiness.industryCardiovascular Diseases/epidemiologyStatinsStatinnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseComorbidityAnticholesteremic Agents/pharmacologyDiabetes Mellitus Type 2/epidemiologyDiabetes Mellitus Type 2Estatines (Medicaments cardiovasculars)Observational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessObservational Study as TopicForecasting
researchProduct

A re-entry tachycardia triggered by the spontaneous interruption of an atrial tachycardia.

2015

The common atrioventricular nodal re-entry tachycardia is the most common form of paroxysmal supraventricular tachycardia. It starts frequently with a supraventricular ectopic beat that, on finding the fast pathway in refractory period, travels in the slow pathway as to appear as a prolongation of the PR interval on the ECG. In this study, we show a singular case of a common atrioventricular nodal re-entry tachycardia triggered by the spontaneous interruption of an atrial tachycardia.

MaleTachycardiacongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtySettore MED/09 - Medicina InternaRefractory periodSlow pathwayEctopic beatParoxysmal supraventricular tachycardiaElectrocardiographyInternal medicineTachycardia Supraventricularmedicinere-entry tachycardia atrial tachycardiaHumansTachycardia Atrioventricular Nodal Reentrycardiovascular diseasesAtrial tachycardiaAgedFast pathwaybusiness.industryRe entryGeneral Medicinemedicine.diseasesurgical procedures operativecardiovascular systemCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Time-restricted eating effects on performance, immune function, and body composition in elite cyclists: a randomized controlled trial.

2020

Abstract Background Although there is substantial interest in intermittent fasting as a dietary approach in active individuals, information regarding its effects in elite endurance athletes is currently unavailable. The present parallel randomized trial investigated the effects of a particular intermittent fasting approach, called time-restricted eating (TRE), during 4 weeks of high-level endurance training. Methods Sixteen elite under-23 cyclists were randomly assigned either to a TRE group or a control group (ND). The TRE group consumed 100% of its estimated daily energy needs in an 8-h time window (from 10:00 a.m. to 6:00 p.m.) whilst energy intake in the ND group was distributed in 3 me…

MaleTime FactorsElite cyclists Endurance Immune system Inflammation Intermittent fastingPhysiologyIntermittent fastinglaw.inventionEnduranceLeukocyte Count0302 clinical medicineRandomized controlled trialWeight losslawIntermittent fastingElectric ImpedanceTestosteroneInsulin-Like Growth Factor INutrition and DieteticsFastingCreatinineBody Compositionmedicine.symptomlcsh:RC1200-1245lcsh:Nutrition. Foods and food supplySettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieBioelectrical impedance analysisResearch ArticleElite cyclistslcsh:TX341-641030209 endocrinology & metabolismClinical nutritionAthletic Performance03 medical and health sciencesYoung AdultEndurance trainingWeight LossmedicineHumansLymphocyte Countlcsh:Sports medicineInflammationbusiness.industryInterleukin-6Elite cyclists; Endurance; Immune system; Inflammation; Intermittent fasting030229 sport sciencesTransforming Growth Factor alphaGas analyzerBicyclingDietSports Nutritional Physiological PhenomenaImmune systemAthletesBasal metabolic rateBasal MetabolismbusinessEnergy IntakeFood ScienceJournal of the International Society of Sports Nutrition
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct

Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331…

2015

Diabetes has been defined on the basis of different biomarkers, including fasting plasma glucose (FPG), 2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the effect of different diagnostic definitions on both the population prevalence of diabetes and the classification of previously undiagnosed individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health examination surveys in different regions.

Maleendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGlobal Health0302 clinical medicineEndocrinologyeducation.field_of_studyDiabetis//purl.org/pe-repo/ocde/ford#3.02.18 [https]Diabetes Mellitus/blood/diagnosis/epidemiologySciences bio-médicales et agricolesadultosensibilidad y especificidadhealth survey3. Good healthpriority journalCARDIOVASCULAR-DISEASEdiabetes mellitusmedicine.medical_specialtyglucosa sanguíneaSurvey samplingoral glucose tolerance test.Medical sciencesSensitivity and SpecificityArticleEndocrinology Diabetes and Metabolism; Internal Medicine; EndocrinologyEffects of diabetesHemoglobin A Glycosylated/metabolism03 medical and health sciencesfalse positive resultSDG 3 - Good Health and Well-beingDiabetes prevalenceDiabetes MellitusSYSTEMATIC ANALYSISHumanshumandiagnostic test accuracy studygross national productOLDER-ADULTSeducationprueba de tolerancia a la glucosaglycosylated hemoglobinHEMOGLOBIN A(1C) MEASUREMENTVLAGGlycated HemoglobinHemoglobin A GlycosylatedScience & TechnologyBlood Glucose/metabolismnutritional and metabolic diseasesGlucose Tolerance Testeconomic aspectmedicine.diseaseglucose blood levelGlucoseEndocrinologyagechemistryFaculdade de Ciências SociaisGlucosaGlobal surveillance of diabetesTOLERANCE TESTWORLDWIDE STANDARDIZATIONBiomarkersBiomedical sciencesBlood GlucoseSettore MED/09 - Medicina InternaNutrition and DiseasehumanosBiomarkers/metabolismInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologygeographychemistry.chemical_compoundVoeding en ZiekteDiagnosisPrevalenceMedicine and Health Sciencesvigilancia centinela030212 general & internal medicinehemoglobin A1cUS POPULATIONDiabetes diagnosisGlucose tolerance testINSULIN-RESISTANCEmedicine.diagnostic_testResearch Support Non-U.S. Gov'tQDiabetesprevalenciaSCREENING-TESThealthArticlesGlucose bloodDiabetes and MetabolismincomePopulation-based health examination surveysFemaleLife Sciences & BiomedicineAdultPopulationpopulation groupCONSENSUS STATEMENT030209 endocrinology & metabolismGLYCATED HEMOGLOBINhigh income regionEndocrinology & MetabolismInsulin resistanceResearch Support N.I.H. ExtramuralbloodInternal medicineDiabetes mellitusparasitic diseasesJournal ArticlemedicineInternal MedicineLife Scienceddc:613business.industryInsulinbody massBiological markerFASTING PLASMA-GLUCOSECiencias socio biomédicasGlycated hemoglobinbusinessmetabolismSentinel Surveillance
researchProduct

Gastric relaxation induced by glucagon-like peptide-2 in mice fed a high-fat diet or fasted.

2011

Glucagon-like peptide-2 (GLP-2) is a nutrient-responsive gut hormone that increases the intestinal absorption. Exogenous GLP-2 also induces gastric fundus relaxation with possible implications for emptying rate or feeling of satiety. GLP-2 actions are mediated by GLP-2 receptor (GLP-2R), located on enteric neurons and myofibroblasts in murine gastrointestinal tract. Because it is not known whether changes in the endogenous GLP-2R levels occur in different nutritional states, we examined the GLP-2R gene and protein expression in gastric fundus from standard diet (STD)-fed, 12-h and 24-h fasted and re-fed, or high-fat diet (HFD)-fed mice and we analyzed the mechanical responses to exogenous G…

Maleendocrine systemmedicine.medical_specialtyGLP-2 receptor expressionPhysiologyEndogenyBiologyDiet High-FatBiochemistrySettore BIO/09 - FisiologiaIntestinal absorptionCellular and Molecular NeuroscienceMiceEndocrinologyInternal medicineIntestine SmallmedicineGlucagon-Like Peptide 2Receptors GlucagonAnimalsObesityGastric FundusReceptorGastrointestinal tractStomachdigestive oral and skin physiologyFastingGlucagon-like peptide-2Up-RegulationBlotMice Inbred C57BLEndocrinologymedicine.anatomical_structureGlucagon-Like Peptide-2 ReceptorGLP-2hormones hormone substitutes and hormone antagonistsHormonePeptides
researchProduct

Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes

2010

Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbA1c] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased …

Malehigh-density lipoproteinsmedicine.medical_specialtyType 2 diabetes030204 cardiovascular system & hematologysizeStatistics NonparametricRosiglitazone03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicinelow-density lipoproteinsHumansHypoglycemic AgentsProspective Studies030212 general & internal medicineGlycated Hemoglobindiabetesbusiness.industryFastingMiddle AgedPostprandial Periodmedicine.diseaseLipids3. Good healthLipoproteins LDLPostprandialEndocrinologyDiabetes Mellitus Type 2FemaleThiazolidinedioneslipids (amino acids peptides and proteins)HemoglobinsubclassesLipoproteins HDLCardiology and Cardiovascular MedicineRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugLipoprotein
researchProduct

Muscle fiber-type distribution predicts weight gain and unfavorable left ventricular geometry: a 19 year follow-up study

2006

Abstract Background Skeletal muscle consists of type-I (slow-twitch) and type-II (fast-twitch) fibers, with proportions highly variable between individuals and mostly determined by genetic factors. Cross-sectional studies have associated low percentage of type-I fibers (type-I%) with many cardiovascular risk factors. Methods We investigated whether baseline type-I% predicts left ventricular (LV) structure and function at 19-year follow-up, and if so, which are the strongest mediating factors. At baseline in 1984 muscle fiber-type distribution (by actomyosin ATPase staining) was studied in 63 healthy men (aged 32–58 years). The follow-up in 2003 included echocardiography, measurement of obes…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemTime Factors030204 cardiovascular system & hematologyDoppler echocardiographyWeight GainBody fat percentageCohort StudiesVentricular Dysfunction Left0302 clinical medicineReference Valuesmedicine.diagnostic_testIncidenceBiopsy NeedleMiddle AgedEchocardiography Dopplermedicine.anatomical_structureMuscle Fibers Slow-TwitchCardiovascular DiseasesMuscle Fibers Fast-TwitchCardiologyRegression Analysismedicine.symptomCardiology and Cardiovascular MedicineResearch ArticleAdultmedicine.medical_specialtyWaistRisk AssessmentSensitivity and Specificity03 medical and health sciencesAge DistributionPredictive Value of TestsInternal medicineHeart ratemedicineHumansObesityMuscle SkeletalAngiologyAgedProbabilityRetrospective Studiesbusiness.industrySkeletal muscle030229 sport sciencesMyocardial ContractionBlood pressurelcsh:RC666-701businessWeight gainFollow-Up StudiesBMC Cardiovascular Disorders
researchProduct

Healthy and unhealthy eating at lower secondary school in Norway

2010

Aims: To assess adolescents’ eating/drinking habits of a selection of healthy and unhealthy food items at school, variations in gender and socioeconomic status in these eating habits, and variations between the schools. Methods: A cross-sectional study among 2870 adolescents (mean age: 15.5 years) within the Fruits and Vegetables Make the Marks (FVMM) project. A survey questionnaire was completed by the pupils in the classroom in the presence of a trained project worker. One school lesson (45 minutes) was used to complete the questionnaire. A total of two healthy (fruit and vegetables (FV), water) and five unhealthy (candy and/or potato chips, sweet bakery, instant noodles, regular soft dr…

Malemedicine.medical_specialtyAdolescenteducationDrinking BehaviorCarbonated BeveragesHealth PromotionCandySurveys and QuestionnairesEnvironmental healthVegetablesmedicineHumansEating habitsLife StyleSocioeconomic statusSchoolsNorwaybusiness.industryPublic healthdigestive oral and skin physiologyPublic Health Environmental and Occupational HealthMean ageFeeding BehaviorGeneral MedicineDietUnhealthy foodCross-Sectional StudiesDrinking habitsSocioeconomic FactorsAdolescent BehaviorFruitFast FoodsVariance componentsFemaleUnhealthy eatingbusinessScandinavian Journal of Public Health
researchProduct